Innovative Therapies, Inc. v. Meents

302 F.R.D. 364, 2014 U.S. Dist. LEXIS 27119, 2014 WL 858651
CourtDistrict Court, D. Maryland
DecidedMarch 4, 2014
DocketCivil Action No. DKC 12-3309
StatusPublished
Cited by16 cases

This text of 302 F.R.D. 364 (Innovative Therapies, Inc. v. Meents) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Innovative Therapies, Inc. v. Meents, 302 F.R.D. 364, 2014 U.S. Dist. LEXIS 27119, 2014 WL 858651 (D. Md. 2014).

Opinion

MEMORANDUM OPINION

DEBORAH K. CHASANOW, District Judge.

Presently pending and ready for review in this declaratory judgment action are several motions, including: (1) the motion of Plaintiff Innovative Therapies, Inc. (“ITI” or “Plaintiff’) for a protective order (ECF No. 21); (2) Plaintiffs motion to modify a subpoena (ECF No. 24); (3) the motion of Defendant Mark S. Meents (“Meents” or “Defendant”) for extension of time to complete discovery (ECF No. 27); and (4) Plaintiffs motion for partial summary judgment (ECF No. 35). The issues have been fully briefed, and the court now rules, no hearing being deemed necessary. Local Rule 105.6. For the following reasons, Plaintiffs motion for partial summary judgment will be denied. Plaintiffs motions for a protective order and to modify a subpoena will be granted in part. Defendant’s motion for an extension of time to complete discovery will be granted in part.

I. Background

ITI is a Delaware medical device company specializing in advanced wound care that was founded in 2005 by Richard Vogel (“Vogel”) and Dr. Paul Svedman. (ECF No. ¶ 5). Meents joined ITI in late 2006. (Id. ¶ 6). On October 15, 2007, Meents was elected to ITI’s Board of Directors as ITI’s Vice President. He received 4,000 shares of ITI’s nonvoting Class A common stock in connection with his employment with ITI. (Id. ¶ 7). Meents executed a Shareholders Agreement with ITI in 2007. (ECF No. 1-6).1 The Shareholders Agreement states that any shareholder may be terminated “for adequate cause.” (ECF No. 1-6, at 15). Under Section 1.10, “adequate cause” includes the following:

(d) a Shareholder fails to perform his duties in a competent manner; (e) a Shareholder violates his duties of confidentiality and/or non-eompete clauses under this Agreement; (f) a Shareholder commits any material act or acts which harm the Company’s reputation, standing, or credibility within the community(ies) it operates or with its customers or suppliers; and (g) a Shareholder fails to perform the duties assigned him in a material manner for whatever reason.

(Id.). Section 1.10 also stipulates that “[i]n the event that a Shareholder is terminated for adequate cause, the terminated Shareholder shall forfeit his stock.” Section 1.9 states that “[i]f a Shareholder voluntarily retires or resigns without meeting the requirements of Section 1.8.1., he shall forfeit his [sjtock.” (Id.). Section 1.8.1. contains the following provision:

Provided that the retired Shareholder has provided the Company and the remaining Shareholders with six (6) months notice, the Company shall have forty-five (45) days from such Notice in which to elect to buy all or any of the retiring Shareholder’s shares of Offered Stock at the Agreement Price in accordance with the provisions below. In the event that the Company fails to purchase any or all of the Offered Stock, each Shareholder shall have fifteen (15) days from the expiration of the Company’s option period described in this Section 1.8.1. in which to buy such remaining shares of the Offered Stock at the Agreement Price in proportion to his respective ownership of the Stock (excluding the Offered Stock), or in such other proportion as the remaining Shareholders shall agree upon in writing, and in accordance with the provision below.

(Id. at 13-14).

ITI designated Meents as its Chief Operating Officer (“COO”) on July 1, 2009 and the parties entered into an Employment Agreement memorializing this relationship on June 10, 2010. (ECF No. 1-4). Article III.C of the Employment Agreement governs termination for cause, and states that “[i]f ITI terminates your employment for [clause ... you shall be entitled to no compensation or benefits from ITI other than those earned.” (Id. at 3). Article III.C explains that a ter[369]*369mination “for cause” occurs if ITI terminates employment for any of the following reasons:

theft, dishonesty, or falsification of any employment or ITI records; ... your consistent poor performance, as determined by your supervisor, in their sole discretion; your improper use or disclosure of ITI’s confidential or proprietary information; any intentional act by you that has a material detrimental effect on ITI’s reputation or business; or any material breach of the terms of this letter agreement by you, which breach is not cured within thirty (30) days following written notice of such breach from ITI.

(Id.).

On April 15, 2011, Meents’s title changed from COO to Vice President of Marketing. Plaintiff alleges that as COO, Mr. Meents “failed to meet previously established goals and objectives while overbuilding ITI’s rental assets and placing ITI in financial distress.” (ECF No. 1 ¶ 15). Meents’s alleged demotion was announced at a staff meeting, during which Vogel explained that “only their longstanding professional relationship had prevented Meents’ prior termination for poor performance.” (Id.). Then, in September 2011, Meents became Vice President of Sales Operations, “a position primarily concerned with the integration of ITI’s sales and billing systems.” (Id. ¶ 16). Creed Russon (“Rus-son”), Meents’s former subordinate, supervised Meents in this new role. ITI allegedly informed Meents that “his latest demotion was a last and final attempt to salvage his ongoing employment with ITI.” (Id. ¶ 17).

As Vice President of Sales Operations, Meents was tasked with the oversight and implementation of a website that would allow ITI’s customers to place orders. According to Plaintiff, “Meents consistently missed deadlines, exceeded his projected budget, and was unable to work with his peers to develop the web-based system. Instead, Meents attempted to implement his own system, which produced inaccurate data and failed to meet the needs of ITI and its customers.” (Id. ¶ 18).

Meents submitted a resignation letter, dated April 16, 2012, in which he stated:

Due to a variety of personal reasons, I am giving my six-month notice of resignation to the company effective October 31, 2012. The effective date of my resignation is per the requirement of section 1.8.1 of the Shareholder’s Agreement dated 10/16/2007. The Shareholder’s Agreement in section 1.8.1 states that I provide this same notice to all other shareholders. Therefore, I am sending this letter to the shareholders copied below who are part of the Shareholders Agreement.

(ECF No. 1-8) (emphasis added). On July 5, 2012, Meents sent the following email to Vogel:

I would like to pursue the sale of my ITI stock. While I realize the time has elapsed for the company or shareholders to purchase, I thought I would ask if there is any interest from inside ITI before pursuing someone outside the company. If there is no internal interest, I will need a method to value my stock to an outside investor.

(ECF No. 36-10). In that email, Meents also asked for access to the following documents that he thought would assist him in valuing his shares of stock: last three years’ finan-cials; incorporation documents including Articles of Incorporation and by-laws. (Id.). On July 10, 2012, Meents met with Vogel, David Tumey (“Tumey”), another shareholder at ITI, and Russon to discuss this email. Meents sent this follow-up email on July 19, 2012 to Vogel, Tumey, and Russon:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
302 F.R.D. 364, 2014 U.S. Dist. LEXIS 27119, 2014 WL 858651, Counsel Stack Legal Research, https://law.counselstack.com/opinion/innovative-therapies-inc-v-meents-mdd-2014.